GH Research (NASDAQ:GHRS) Trading Up 4.1% – Still a Buy?

Shares of GH Research PLC (NASDAQ:GHRS) rose 4.1% during trading on Tuesday . The company traded as high as $9.66 and last traded at $9.41. Approximately 15,035 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 79,072 shares. The stock had previously closed at $9.04.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GHRS shares. JMP Securities reissued a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of GH Research in a research report on Thursday, September 5th.

GH Research Trading Down 2.9 %

The stock has a market cap of $466.71 million, a P/E ratio of -13.82 and a beta of 0.74. The firm’s 50-day simple moving average is $7.74 and its 200 day simple moving average is $10.39.

GH Research (NASDAQ:GHRS) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. On average, analysts anticipate that GH Research PLC will post -0.85 EPS for the current year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP boosted its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the period. GH Research makes up approximately 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th biggest position. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).